title: [Combination of rituximab with combined pulse-therapy with high doses of methylprednisolone and cyclophosphamide: effects on immunomorphological and functional disturbances of the salivary glands in a patient with Sjogren's disease and MALT-lymphoma].
authors.forename: V I
authors.initials: VI
authors.lastname: Vasil'ev
authors.forename: N V
authors.initials: NV
authors.lastname: Kokosadze
authors.forename: O A
authors.initials: OA
authors.lastname: Logvinenko
authors.forename: E A
authors.initials: EA
authors.lastname: Nikitin
authors.forename: B V
authors.initials: BV
authors.lastname: Mitrikov
authors.forename: E B
authors.initials: EB
authors.lastname: Rodionova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Varlamova
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D018442:Lymphoma, B-Cell, Marginal Zone / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D020551:Pulse Therapy, Drug; D000069283:Rituximab; D012472:Salivation / Q000187:drug effects*; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013363:Submandibular Gland / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D003520:Cyclophosphamide; D008775:Methylprednisolone